beta
Trial Radar AI
Clinical Trial NCT05053607 for Multiple Myeloma, Refractory Multiple Myeloma is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One trial matched filter criteria
Card View
Back to Search

Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab

Recruiting
Clinical Trial NCT05053607 is an interventional study for Multiple Myeloma, Refractory Multiple Myeloma that is recruiting. It started on June 17, 2022 with plans to enroll 50 participants. Led by Pack Health, it is expected to complete by December 31, 2025. The latest data from ClinicalTrials.gov was last updated on December 11, 2024.
Brief Summary
This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative and wearable data. Fifty adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc will be enrolled across 2 sites, The University of California San Francisco and The University of Texas MD Anderson Cancer Center. Consented participants will be enrolled in a 3-month digital health coaching program through which electronic patient reported outcomes and wearable activity data will be collected. Outcomes include treatment experience, quality of life, financial toxicity, treatment adherence, symptom burden and health self-efficacy. These will be captured by patient reported outcome measures including the Patient's Qualitative Assessment of Treatment- Real World (PQAT-RW), Patient Global Impression of Change/Severity (PGIC/S), European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30), Quality of Life Questionnaire Multiple Myeloma (QLQ-MY20), and the European QoL-5 Dimensions (EQ5D), Cancer Behavior Inventory-Brief Form (CBI-B), Center for Adherence Support Evaluation (CASE) Medication Adherence Index, Comprehensive Score for Financial Toxicity (COST) Instrument.

Clinical data, including treatment history, healthcare utilization, and co-morbidities, as well as demographic data will be collected via the electronic health record from each clinical site. This data will be complemented by qualitative data from a selected cohort of study participants with a focus on treatment experience ranging from infusion burden, toxicity management, to overall quality of life. Evaluation of this data in combination will be used to better understand the treatment experience of individuals on standard of care isatuximab-irfc specifically, and with relapsed or refractory multiple myeloma generally, contributing to an existing gap in the literature regarding patient reported outcomes from diverse data sources. Outcomes will be analyzed with attention to the relationship between social determinants of health, including race, ethnicity, and geographic location, and treatment experience as reflected in both the qualitative and quantitative data.

Official Title

Clinical and Patient Reported Outcomes for Individuals with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab: Real-World Insights from Patient Reported, Wearable, and Qualitative Data in the Context of Digital Health Coaching

Conditions
Multiple MyelomaRefractory Multiple Myeloma
Publications
Scientific articles and research papers published about this clinical trial:
Show More
Other Study IDs
  • 2021-0309
NCT ID Number
NCT05053607
Start Date (Actual)
2022-06-17
Last Update Posted
2024-12-11
Completion Date (Estimated)
2025-12-31
Enrollment (Estimated)
50
Study Type
Interventional
PHASE
N/A
Status
Recruiting
Keywords
isatuximab
wearable electronic devices
qualitative research
patient reported outcome measures
Primary Purpose
Other
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
Other1. Single Arm Cohort Receiving Digital Health Coaching
All study participants will be enrolled in a 3-month digital health coaching program. They will also receive a Fitbit device to be worn daily for the capture of physical activity data. Participants have the option to participate in a one time interview about their treatment experience.
Digital Health Coaching Program
consisting of weekly calls and delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.
Fitbit
A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Change in Patient's Qualitative Assessment of Treatment Real World version (PQAT-RW)
A 6-item survey assessing experience of a drug during clinical trial. The instrument consists of 3-free text and 3 scaled responses assessing the perceived benefits and disadvantages of received treatment and willingness to continue on drug after the study.
Change in baseline perception of treatment experience at 3 months
Qualitative Interview
A one time interview will be conducted to learn more about the experience of individuals related to their diagnosis, treatment, symptoms, side effects and overall care experience.
Within the last month of study participation
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)
A 30-item measure of quality of life across 5 domains, including physical, emotional, social, role and cognitive), 8 symptoms, and items assessing global health and financial toxicity. Recall over the past week is scored primarily on a 4-point scale ranging from "not at all" to "very much". The instrument may be administered either on paper or electronically.
Change in baseline perception of treatment experience at 3 months
Change in Quality of Life Questionnaire Multiple Myeloma (QLQ-MY20)
A 20-item measure of quality of life among individuals with multiple myeloma. It assesses a series of symptoms on a 4-point Likert scale ranging from 1 (Not at All) to 4 (Very Much).
Change in baseline perception of treatment experience at 3 months
Change in European QoL-5 Dimensions (EQ5D)
A measure of quality of life across 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Change in baseline perception of treatment experience at 3 months
Change in Cancer Behavior Inventory-Brief Form (CBI-B)
This 12-item instrument measures self-efficacy in coping with cancer across 7 domains. These include: Seeking and Understanding Medical Information, Emotion Regulation, Coping with Treatment Related Side Effects, Accepting Cancer/ Maintaining a Positive Attitude, Seeking Social Support, and Using Spiritual Coping. The instrument utilizes a 9-point response scale ranging from 1 "Not at all confident" to 9 "Confident".
Change in baseline perception of treatment experience at 3 months
Change in Patient Global Impression of Severity (PGIS) Scale
A 1-item measure of severity of relapsed/refractory multiple myeloma symptoms since the last visit, which is scored a on a 5-response scale ranging from "none" to "very severe".
Change in baseline perception of treatment experience at 3 months
Change in Patient Global Impression of Change (PGIC) Scale
A 1-item measure of patient perception of change in relapsed/refractory multiple myeloma symptoms since starting a study. Responses are scored on a 7-point scale, ranging from "very much worse" to "very much better".
Change in baseline perception of treatment experience at 3 months
Change in Center for Adherence Support Evaluation (CASE) Medication Adherence Index
The Center for Adherence Support Evaluation (CASE) is a three-item questionnaire used to measure antiretroviral therapy adherence. This questionnaire was developed through the Special Projects of National Significance (SPNS) initiative called Assessing Existing Efforts to Increase Adherence to Medication. Patients take less than 5 minutes to answer the three unique questions, asking about their difficulty taking medications on time, average days per week with one dose missed, and the last time they missed a dose.
Change in baseline perception of treatment experience at 3 months
Change in Comprehensive Score for Financial Toxicity (COST) Instrument
The Comprehensive Score for Financial Toxicity (COST) is an 11-item instrument used to measure the financial toxicity of cancer treatment, which has been demonstrated to be highly correlated with HRQoL (de Souza et al., 2017). This instrument was validated among individuals with advanced cancer and demonstrated high internal consistency (Cronbach's α \>.90) and highly correlated to HRQol (p=.05). The instrument consists of 11 items, utilizing a five-point ordinal scale ranging from (0- Not at all) to (4- Very much).
Change in baseline perception of treatment experience at 3 months
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  • Age 18 or older
  • Diagnosis of relapsed/refractory multiple myeloma corresponding to the Food and Drug Administration (FDA) package insert for isatuximab-irfc (Sarclisa®).
  • Confirmed or planned treatment with intravenous isatuximab-irfc for relapsed/refractory multiple myeloma as standard-of-care therapy. Concurrent therapy with other agents (e.g., pomalidomide) is allowed.
  • Access to and willingness to use a smartphone or other device through which they can send and receive text messages, emails and/or access a mobile application.
  • Willingness to wear and have data collected by a Fitbit
  • Ability to engage in physical activity as evidenced by an Eastern Cooperative Oncology Group (ECOG) performance status score of less than or equal to 2

  • Individuals who are terminally ill, defined as individuals identified by their physician as likely having 6 months or less to live, or those individuals transitioned to comfort measures only (meaning only supportive care measures without curative focused treatment)
  • Individuals for whom there is documentation of inability to provide consent in the medical record.
  • Individuals receiving isatuximab-irfc subcutaneously
Pack Health logoPack Health
Study Central Contact
Contact: Kelly J Brassil, PhD, 205-721-7542, [email protected]
Contact: Jennifer Loftis, DNP, 205-721-7542, [email protected]
2 Study Locations in 1 Countries

Texas

The University of Texas MD Anderson Cancer Center, Houston, Texas, 77074, United States
Active, not recruiting

Washington

University of Washington, Seattle, Washington, 98109, United States
Trenton Grossfeld, BS, Contact, 206-606-1774, [email protected]
Rahul Banerjee, MD, Contact
Recruiting